PHENO LOCK

Serial Number 97626317
Registration 7201861
700

Registration Progress

Application Filed
Oct 10, 2022
Under Examination
Approved for Publication
Aug 8, 2023
Published for Opposition
Aug 8, 2023
Registered
Oct 24, 2023

Basic Information

Serial Number
97626317
Registration Number
7201861
Filing Date
October 10, 2022
Registration Date
October 24, 2023
Published for Opposition
August 8, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 24, 2023
Registration
Registered
Classes
001 005 040

Rights Holder

Quell Therapeutics Limited

99
Address
3rd Floor, Translation & Innovation Hub
84 Wood Lane
London W120BZ
GB

Ownership History

Quell Therapeutics Limited

Original Applicant
99
London GB

Quell Therapeutics Limited

Owner at Publication
99
London GB

Quell Therapeutics Limited

Original Registrant
99
London GB

Legal Representation

Attorney
Carlynn Ferguson

USPTO Deadlines

Next Deadline
1568 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-10-24)
Due Date
October 24, 2029
Grace Period Ends
April 24, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

33 events
Date Code Type Description
Jun 5, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 5, 2025 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 5, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 5, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 13, 2024 NURC C NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Jan 5, 2024 A7OK O AMENDMENT UNDER SECTION 7 - PROCESSED
Jan 4, 2024 ES7R I TEAS SECTION 7 REQUEST RECEIVED
Nov 18, 2023 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 31, 2023 ES7R I TEAS SECTION 7 REQUEST RECEIVED
Oct 24, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 24, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER
Sep 20, 2023 CHPB I POST PUBLICATION AMENDMENT - ENTERED
Sep 20, 2023 APET A ASSIGNED TO PETITION STAFF
Aug 29, 2023 EPPA I TEAS POST PUBLICATION AMENDMENT RECEIVED
Aug 8, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 8, 2023 PUBO A PUBLISHED FOR OPPOSITION
Jul 19, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 30, 2023 FIXD O ELECTRONIC RECORD REVIEW COMPLETE
Jun 23, 2023 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jun 22, 2023 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 22, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED
Jun 22, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 22, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED
Jun 22, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN
May 20, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
May 19, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
May 19, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 27, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 27, 2023 GNRT F NON-FINAL ACTION E-MAILED
Feb 27, 2023 CNRT R NON-FINAL ACTION WRITTEN
Feb 16, 2023 DOCK D ASSIGNED TO EXAMINER
Oct 25, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 13, 2022 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 001
Class 1: Chemical and biological preparations for use in science and industry; chemical and biological preparations for non-medical purposes; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; immunological agents and preparations for non-medical purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; nucleic recombinant acids; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry
Class 005
Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely, stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; [ Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely, for medical conditions caused by the immune system; ] pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection
Class 040
Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products

Additional Information

Other
In the statement, line 39 through line 41, "Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely for medical conditions caused by the immune system;" is deleted.

Classification

International Classes
001 005 040